Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut over the last week.
- Enesi Pharma, an Oxford-based biotech developing novel needle-free vaccines, is partnering with Public Health England to develop vaccines for emergent threat pathogens
- German Bayer spin-off AiCuris will collaborate with Canadian biotech Cyclenium Pharma to use their combined expertise in infectious diseases to develop new treatments for bacterial and viral infections
- French CAR-Treg autoimmune-disease biotech TxCell has completed the final details of its acquisition deal and become a subsidiary of US-based Sangamo Therapeutics, which plans to develop the technology further
- French company Novasep has opened €27M facility in Seneffe, Belgium to produce viral vectors for use in gene therapies, a rapidly growing field
- The opium poppy genome has been assembled thanks to a Chinese, English and Israeli collaboration, which the researchers hope will lead to the development of more affordable and reliable medicines
- Swedish company BioArctic has been granted a European patent for an implant that is designed to treat complete spinal cord injury
- A branch of UK-based Premaitha Health, a molecular diagnostics company, will partner with an unspecified clinical research organisation in Taiwan to provide next generation sequencing services for oncology patients
- US-based IQVIA and Genomics England will develop a research platform for scientists combining clinical and genomic data to help advance the development of personalized medicines
- US-biotech bluebird bio’s LentiGlobin one-time gene therapy for treatment of transfusion-dependent β-thalassemia has had its marketing authorisation application accepted in Europe
- London-based venture capital firm Arix Bioscience invested €50M in series A funding for US-biotech VelosBio, which is developing antibody-drug conjugates for treating blood cancer and solid tumors
- Cambridge-based synthetic biology company Evonetix aims to scale up its DNA synthesis technology by partnering with Dutch customised microsystem company LioniX International
- SynbiCITE, the national centre for commercialization of synthetic biology in the UK, announced the launch of a new 5-year strategy that will be funded by a €5.7M grant from UK Research and Innovation, as well as other investors
Images: E. Resko & Shutterstock
Let's Continue The Conversation
Feel free to send us comments about this article to email@example.com and/or comment on that article on social media.